Economic evaluation of medical technologies in Sweden

被引:9
作者
Jonsson, B
机构
[1] Stockholm School of Economics, S-113 83 Stockholm
关键词
economic evaluation; technology assessment; health policy; Sweden;
D O I
10.1016/S0277-9536(96)00399-1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This paper reviews the use of economic evaluations in the Swedish health care system. The most important actors are defined and examples are given how economic evaluations have played a role in the decision making process. The introduction of extracorporal shock-wave lithotripsy (ESWL) is used as an example on how economic evaluation was used for recommendations to the county councils to adopt this technology. Mammography is used as an example of how the evaluation is used in the political process following an initiative in the parliament. A study of the cost-effectiveness of hypertension treatment illustrates how economic evaluations are included as part of a medical technology assessment by SBU, the Swedish Council on Technology Assessment in Health Care. The role of economic evaluations for drug reimbursement and pricing is also reviewed. The main conclusions are that economic evaluations are one of several factors influencing a decision making process that have a strong strive for consensus. It is thus difficult to make a definitive statement of the contribution of such study to the outcome of the decision making process, and there is no evidence that the evaluation was the decisive factor. However, a number of changes in the way resources are allocated in the Swedish health care system speaks for an increasing role for such studies in the future. The county councils are identified as the main target for economic evaluations, and SBU has a key role in supplying the county councils with high quality assessment of new and old technologies. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:597 / 604
页数:8
相关论文
共 16 条
[1]  
Carlsson P, 1989, Scand J Urol Nephrol Suppl, V122, P44
[2]  
CARLSSON P, 1989, SCANDINAVIAN J URO S, V122, P1
[3]  
JONSSON B, 1976, THESIS LIBER
[4]   HEALTH-CARE TECHNOLOGY IN SWEDEN [J].
JONSSON, E ;
BANTA, HD .
HEALTH POLICY, 1994, 30 (1-3) :257-294
[5]   COST-EFFECTIVENESS OF THROMBOLYSIS - A RANDOMIZED STUDY OF INTRAVENOUS RT-PA IN SUSPECTED MYOCARDIAL-INFARCTION [J].
LEVIN, LA ;
JONSSON, B .
EUROPEAN HEART JOURNAL, 1992, 13 (01) :2-8
[6]  
LINDHOLM B, 1973, 1 STAT MED FORSKN
[7]   COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH TISSUE-PLASMINOGEN ACTIVATOR AS COMPARED WITH STREPTOKINASE FOR ACUTE MYOCARDIAL-INFARCTION [J].
MARK, DB ;
HLATKY, MA ;
CALIFF, RM ;
NAYLOR, CD ;
LEE, KL ;
ARMSTRONG, PW ;
BARBASH, G ;
WHITE, H ;
SIMOONS, ML ;
NELSON, CL ;
CLAPPCHANNING, N ;
KNIGHT, JD ;
HARRELL, FE ;
SIMES, J ;
TOPOL, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (21) :1418-1424
[8]  
*NLN, 1995, NLN PUBL
[9]  
*OECD, 1995, HLTH CAR SYST 17 COU
[10]  
*SBU, 1995, J INTERNAL MED, V238